Seasoned Financial Executive Will Lead Finance Operations as Biotalys Pushes Product Pipeline Toward Commercialization
Ghent, May 26, 2025 (GLOBE NEWSWIRE) — Press release
Ghent, BELGIUM – 26 May 2025, 07:00 CEST – Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced the appointment of Luc Van fraeyenhoven as Chief Financial Officer (CFO). He succeeds Douglas Minder, who will pursue other career opportunities. Mr. Van fraeyenhoven will transition into the role over the next few months.
With more than three decades in financial roles, Mr. Van fraeyenhoven brings significant experience as a CFO in the biotechnology and medtech industries, with a strong background leading finance operations and strategy in addition to partnering closely with the boards of various companies throughout his career. He has served as the CFO for Arseus Medical, ActoBio Therapeutics, the Akkermansia Company, and most recently with the Kebony Group. He also has extensive prior finance leadership experience with Volvo Cars, serving in roles of increasing responsibility including as CFO for the commercial entity in Europe.
Simon Moroney, Chairman of the Board at Biotalys, commented: “Luc joins us at an important juncture in the company as we continue to advance our innovative product pipeline, and we look forward to his engagement in providing financial guidance on both long-term strategies and day-to-day operations. We are grateful to Douglas for his many contributions to Biotalys, particularly as we streamlined operations and extended our financial runway. We wish him all the best as he pursues new opportunities.”
Kevin Helash, CEO of Biotalys, noted: “Luc will be a valuable partner for the management and board as we continue to best position the company for the commercialization of our first products while being prudent stewards of our resources. His extensive experience with other companies in the biotechnology arena is an outstanding fit for Biotalys, and we will leverage his considerable leadership as we execute our long-term global strategy.”
Luc Van fraeyenhoven, newly appointed CFO of Biotalys, said: “I am delighted to join the Biotalys team and am eager to be a partner with and resource to the entire organization. Biotalys occupies a unique position in the agricultural and biotech space, and I look forward to contributing to the advancement of this novel, sustainable technology.”
Mr. Van fraeyenhoven, a native of Belgium, holds degrees in commercial engineering and transport economics from the University of Antwerp, and a master’s in financial management from VLEKHO in Brussels.
About Biotalys
Biotalys is an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for the protection of crops and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.
For further information, please contact:
Toon Musschoot, Head of IR & Communication
T: +32 (0)9 274 54 00
E: IR@biotalys.com
Important Notice
Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company’s website.
This announcement contains statements which are “forward-looking statements” or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, ‘believe’, ‘estimate’, ‘anticipate’, ‘expect’, ‘intend’, ‘may’, ‘will’, ‘plan’, ‘continue’, ‘ongoing’, ‘possible’, ‘predict’, ‘plans’, ‘target’, ‘seek’, ‘would’ or ‘should’, and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys’ actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.
- CallTower Launches Entra Sync: Streamlining Microsoft Teams Provisioning and Management - June 25, 2025
- Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director - June 25, 2025
- Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy - June 25, 2025
